引用本文:王 钥,陈 婕,热依扎·努尔苏力坦,吴 梦,张 晨,王小沛,朱 军,宋玉琴,刘卫平.自体造血干细胞移植治疗合并乙型肝炎病毒感染的弥漫大B细胞淋巴瘤患者的有效性和安全性分析[J].中国临床新医学,2023,16(11):1110-1114.
【打印本页】   【下载PDF全文】   查看/发表评论  【EndNote】   【RefMan】   【BibTex】
←前一篇|后一篇→ 过刊浏览    高级检索
本文已被:浏览 318次   下载 691 本文二维码信息
码上扫一扫!
分享到: 微信 更多
自体造血干细胞移植治疗合并乙型肝炎病毒感染的弥漫大B细胞淋巴瘤患者的有效性和安全性分析
王 钥,陈 婕,热依扎·努尔苏力坦,吴 梦,张 晨,王小沛,朱 军,宋玉琴,刘卫平
100142 北京,北京大学肿瘤医院暨北京市肿瘤防治研究所淋巴肿瘤内科,恶性肿瘤发病机制及转化研究教育部重点实验室
摘要:
[摘要] 目的 探讨自体造血干细胞移植(auto-HSCT)治疗合并乙型肝炎病毒(HBV)感染的弥漫大B细胞淋巴瘤(DLBCL)患者的有效性、安全性和生存获益。方法 回顾性分析2008年8月至2020年8月于北京大学肿瘤医院接受auto-HSCT治疗的39例初治合并HBV感染的DLBCL患者资料,采用Kaplan-Meier生存曲线进行生存分析。结果 全组患者移植前后的完全缓解率分别为56.41%和71.79%,移植后3年无进展生存率及总生存率分别为38.46%和58.97%,39例患者均获得造血重建。结论 auto-HSCT用于治疗合并HBV感染的DLBCL是安全有效的,可明显改善患者预后。
关键词:  自体造血干细胞移植  乙型肝炎病毒  弥漫大B细胞淋巴瘤  预后
DOI:10.3969/j.issn.1674-3806.2023.11.02
分类号:R 733.4
基金项目:北京市卫生健康科技成果和适宜技术推广项目(编号:BHTPP2022058);希思科-豪森肿瘤研究基金项目(编号:Y-HS202202-0104)
Analysis of the effectiveness and safety of autologous hematopoietic stem cell transplantation in treatment of diffuse large B-cell lymphoma patients complicated with hepatitis B virus infection
WANG Yue, CHEN Jie, Reyizha Nuersulitan, et al.
Department of Lymphoma, Key Laboratory of Carcinogenesis and Translational Research(Ministry of Education), Peking University Cancer Hospital & Institute, Beijing 100142, China
Abstract:
[Abstract] Objective To explore the effectiveness and safety of autologous hematopoietic stem cell transplantation(auto-HSCT) in treatment of diffuse large B-cell lymphoma(DLBCL) patients complicated with hepatitis B virus(HBV) infection and the benefits of auto-HSCT for the patients′ survival. Methods The data of 39 DLBCL patients complicated with HBV infection who were newly treated with auto-HSCT in Peking University Cancer Hospital from August 2008 to August 2020 were retrospectively analyzed, and Kaplan-Meier(KM) curve was used for survival analysis. Results The complete remission rates of all the included patients before and after auto-HSCT were 56.41% and 71.79%, respectively. The 3-year progression-free survival and overall survival rates after auto-HSCT were 38.46% and 58.97%, respectively. Hematopoietic reconstruction was achieved in all the 39 patients. Conclusion auto-HSCT is safe and effective in treatment of the DLBCL patients complicated with HBV infection, and can significantly improve the prognosis of the patients.
Key words:  Autologous hematopoietic stem cell transplantation(auto-HSCT)  Hepatitis B virus(HBV)  Diffuse large B-cell lymphoma(DLBCL)  Prognosis